167 filings
Page 2 of 9
8-K
k46p5jf4
16 May 22
Vyant Bio Reports First Quarter 2022 Results and Provides Strategic and Business Highlights
8:30am
8-K
wik8foo53rya
8 Apr 22
Entry into a Material Definitive Agreement
7:00pm
8-K
ee27085 xo10bipqsb
1 Mar 22
Vyant Bio Issues Letter to Shareholders
8:30am
8-K
ffpy8 rclzzdiqr71sy
24 Jan 22
Departure of Directors or Certain Officers
9:00am
8-K
vbq hsfwklvcnb
26 Oct 21
Other Events
8:00am
8-K
0gv0 qn5ptzv1cec
16 Aug 21
Vyant Bio Reports Second Quarter 2021 Results and Provides Strategic Business Updates
4:01pm
8-K
3u0gbdj2lszg53tjrnq
17 May 21
Vyant Bio Reports First Quarter 2021 Results and Provides Strategic Business Update
5:27pm
8-K
ypnw6qkoiatrx ccq455
5 Apr 21
Report of Independent Registered Public Accounting Firm
5:12pm
8-K
ybew beiqpudziuulll
25 Mar 21
Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX
9:17am
8-K
bce6 95nqiel8uo
16 Mar 21
Other Events
7:02am
8-K
re9rxz x80o
26 Feb 21
Entry into a Material Definitive Agreement
4:42pm
8-K
fzqku8svg084fwp1hrw
16 Feb 21
Cancer Genetics Announces $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules
4:51pm
8-K
43mu2lpb8ozlwl7d
8 Feb 21
Entry into a Material Definitive Agreement
5:22pm
8-K
xrhaynpcl1 r5vybw
1 Feb 21
Cancer Genetics Announces $10.0 Million Private Placement Priced At-the-Market
5:24pm
8-K
1cxd768p6u964
28 Jan 21
Other Events
3:42pm
8-K
1ipyftjg xyr
8 Jan 21
Regulation FD Disclosure
4:30pm
8-K
kcidz
7 Jan 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:30am
8-K
shly1mx 0nr
2 Dec 20
Entry into a Material Definitive Agreement
9:54pm
8-K
biet qz2upwa38ur86u
2 Dec 20
Other Events
9:53pm
8-K
07l6 ya1496ump3y
20 Nov 20
Entry into a Material Definitive Agreement
5:26pm